PMID- 31183384
OWN - NLM
STAT- MEDLINE
DCOM- 20200113
LR  - 20231011
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2019
DP  - 2019
TI  - A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection 
      and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus 
      Patients: A 26-Week Follow-Up.
PG  - 6423987
LID - 10.1155/2019/6423987 [doi]
LID - 6423987
AB  - OBJECTIVE: To evaluate the effects of once-weekly dulaglutide injection and 
      once-daily glimepiride on glucose fluctuation in patients with type 2 diabetes 
      mellitus (T2DM) using the Continuous Glucose Monitoring System (CGMS). METHODS: A 
      total of 23 patients with T2DM were randomly assigned into two groups for 26 
      weeks: the dulaglutide group (n = 13) and the glimepiride group (n = 10). 72-hour 
      CGMS was applied to all patients: before and after the treatment. General 
      clinical data were collected and measured, such as fasting blood glucose (FBG), 
      glycosylated hemoglobin (HbA1c), tumor necrosis factor-alpha (TNF-alpha), 
      8-iso-prostaglandin F2alpha (8-iso-PGF2alpha), and interleukin-6 (IL-6). RESULTS: HbA1c 
      of the dulaglutide group was reduced from 8.38 +/- 0.93% to 6.68 +/- 0.73% after the 
      treatment (P < 0.05); similarly, it was reduced from 7.91 +/- 0.98% to 6.67 +/- 0.74% 
      (P < 0.05) in the glimepiride group. The levels of serum 8-iso-PGF2alpha, TNF-alpha, and 
      IL-6 all decreased significantly in both groups after treatment, and there was no 
      significant difference found between the two groups (P > 0.05). The Mean Blood 
      Glucose (MBG) of the two groups declined significantly after therapy (P < 0.05). 
      However, the Standard Deviation of Blood Glucose (SDBG) decreased significantly 
      only in the dulaglutide group (from 2.57 +/- 0.74 mmol/L to 1.98 +/- 0.74 mmol/L, P < 
      0.05). There were no significant changes of Mean Amplitude of Glycemic Excursion 
      (MAGE) and Absolute Means of Daily Difference (MODD) after treatment in both 
      groups. Furthermore, no statistically significant difference was found between 
      the two groups in MBG, SDBG, MAGE, and MODD (P > 0.05). The percentage time (PT) 
      (>10 mmol/L and 3.9-10 mmol/L) of the two groups was significantly changed after 
      the treatment (P < 0.05). However, this was not seen in the PT < 3.9 mmol/L after 
      the treatment (P > 0.05). CONCLUSION: Once-weekly dulaglutide injection has the 
      same effectiveness as daily glimepiride on lowering blood glucose and decreasing 
      oxidation stress and inflammation and is more effective in controlling glucose 
      fluctuation as compared with glimepiride. This trial is registered with 
      ClinicalTrials.gov NCT01644500.
FAU - Li, Huiqin
AU  - Li H
AUID- ORCID: 0000-0002-6319-1196
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing 210012, China.
FAU - Xu, Xiaohua
AU  - Xu X
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing 210012, China.
FAU - Wang, Jie
AU  - Wang J
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing 210012, China.
FAU - Kong, Xiaocen
AU  - Kong X
AUID- ORCID: 0000-0002-4254-7384
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing 210012, China.
FAU - Chen, Maoyuan
AU  - Chen M
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing 210012, China.
FAU - Jing, Ting
AU  - Jing T
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing 210012, China.
FAU - Zhang, Zhiying
AU  - Zhang Z
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing 210012, China.
FAU - Yin, Guoping
AU  - Yin G
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing 210012, China.
FAU - Liu, Xiaomei
AU  - Liu X
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing 210012, China.
FAU - Hu, Yun
AU  - Hu Y
AUID- ORCID: 0000-0002-4477-3641
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing 210012, China.
FAU - Ye, Lei
AU  - Ye L
AUID- ORCID: 0000-0001-5039-6224
AD  - National Heart Research Institute Singapore, National Heart Centre Singapore, 
      Singapore.
FAU - Su, Xiaofei
AU  - Su X
AUID- ORCID: 0000-0002-8263-7608
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing 210012, China.
FAU - Ma, Jianhua
AU  - Ma J
AUID- ORCID: 0000-0001-9383-2559
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing 210012, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT01644500
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20190430
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (IL6 protein, human)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Interleukin-6)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 27415-26-5 (8-epi-prostaglandin F2alpha)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 6KY687524K (glimepiride)
RN  - B7IN85G1HY (Dinoprost)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - Blood Glucose/*analysis
MH  - Blood Glucose Self-Monitoring
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dinoprost/analogs & derivatives/metabolism
MH  - *Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Glucagon-Like Peptides/administration & dosage/*analogs & derivatives
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Immunoglobulin Fc Fragments/*administration & dosage
MH  - Inflammation
MH  - Interleukin-6/metabolism
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Ambulatory
MH  - Oxidative Stress
MH  - Recombinant Fusion Proteins/*administration & dosage
MH  - Sulfonylurea Compounds/*administration & dosage
MH  - Tumor Necrosis Factor-alpha/metabolism
PMC - PMC6515022
EDAT- 2019/06/12 06:00
MHDA- 2020/01/14 06:00
PMCR- 2019/04/30
CRDT- 2019/06/12 06:00
PHST- 2018/12/05 00:00 [received]
PHST- 2019/02/20 00:00 [accepted]
PHST- 2019/06/12 06:00 [entrez]
PHST- 2019/06/12 06:00 [pubmed]
PHST- 2020/01/14 06:00 [medline]
PHST- 2019/04/30 00:00 [pmc-release]
AID - 10.1155/2019/6423987 [doi]
PST - epublish
SO  - J Diabetes Res. 2019 Apr 30;2019:6423987. doi: 10.1155/2019/6423987. eCollection 
      2019.